Sleep Supplement Guide: What The Evidence Shows

Start here, because expectation is what makes people abandon a supplement in week two or keep taking one that is doing nothing.

Effect sizes as the studies reported them. They belong to single ingredients at stated doses rather than to any finished product.

Two conclusions follow and they point in different directions. The first is that these are not placebo-only effects: several of them survived randomisation against a placebo arm in people who genuinely could not sleep.

The second is that anybody expecting to be switched off will be disappointed by every product in this aisle. Fifteen minutes and one fewer waking is what a good result looks like here.

Melatonin is the hormone the brain releases as light falls. Taking it is a timing signal rather than a sedative, and that single distinction explains most of what goes wrong with it.

The dose question has an unusually clear answer, and it comes from a study built to ask it. Three strengths were run in the same older adults, a week apart each, the middle of them roughly the amount a body makes for itself. That middle strength was the one that put sleep efficiency back. Ten times as much achieved nothing further.

Set against that, a meta-analysis of nineteen trials found a median dose of about 3 mg across the literature and a range from 0.1 to 10 mg, so the market has settled roughly ten times above the amount that worked in the clearest trial.

The guideline position is worth knowing before buying anything. The American Academy of Sleep Medicine weighs melatonin for chronic insomnia in adults and makes a weak recommendation against it, while the Cochrane review of jet lag is where its evidence is strongest. A shifted clock is what melatonin is good at.

Then there is the content problem, which is specific to this ingredient. An assay of thirty-one melatonin products found label content ranging from 83 per cent below to 478 per cent above what was printed, the commentary published alongside it put the quality control bluntly, and a 2023 JAMA analysis of gummies sold in the US found the same problem intact five years later.

One household point belongs with it. Calls to American poison centres about children swallowing melatonin climbed steeply through the ten years to 2021, which makes where a bottle is kept part of the decision to buy one.

Minerals turn up in sleep formulas because they are cofactors in the pathway that builds serotonin and melatonin out of tryptophan. That is a plausible mechanism and it is a different kind of claim from a sedative one.

Magnesium has the best evidence of the three. Eight weeks of half a gram a day, elemental, in older adults with primary insomnia, produced longer and more efficient sleep against placebo. Pooling three trials that ran between 320 and 720 mg a day puts the shortening of sleep onset at roughly a quarter of an hour.

Two cautions belong beside that. The most recent systematic review is explicit about how few and how small these trials are, an earlier review reaches the same conclusion, and the Institute of Medicine sets the upper intake for supplemental magnesium at 350 mg a day for adults, which the 500 mg trial deliberately exceeded under supervision. Loose stools are the usual first sign of too much.

Vitamin B6 is the coenzyme in the same pathway and its own sleep result is oddly specific. Given at a large dose for five consecutive evenings it produced more dream material in the morning and nothing at all in the sleep measures themselves. The adult ceiling for supplemental B6 is a hundred milligrams a day, and it exists because of nerve damage rather than because of anything to do with sleep; a 2021 review sets out the mechanism. Read a B6 figure on a label for safety, not for effect.

Calcium is the weakest of the three and its evidence is survey evidence. One national dataset puts habitual calcium intake among the nutrients that track how long people sleep. A systematic review of micronutrient status and sleep reads that whole literature as correlation pointing in both directions, which is a long way from a treatment effect.

Valerian is the most-studied herb in this category and it is the clearest example of a problem that runs through the whole aisle.

Almost every positive human result for hops is a valerian-and-hops result. One four-week study ran a single preparation in which the valerian outweighed the hops four to one. A multicentre study set against an antihistamine used a tablet with a similar imbalance. A 2025 feasibility study went back to the same combined preparation for a third time.

So a product containing hops and no valerian cannot read those trials across to itself, and a great many products do exactly that. The only hops-alone human signal in the literature is 333 mL of non-alcoholic beer with supper in a small study of shift nurses.

Lemon balm has the same shape of problem from the other direction. Its best-known anxiolytic result comes from a combination with valerian, while the single-herb crossover found a 600 mg dose attenuated a laboratory stressor where 300 mg in the same people did not.

NCCIH’s own summary of valerian is a reasonable place to start on the herb itself. The general lesson is the useful part: when an ingredient’s reputation comes from a fixed combination, check whether the other half of the combination is in the bottle.

These three are usually described the same way: constituents that interact with the GABA system, the brain’s main braking mechanism, far more gently than a sedative does.

Chamomile has the most human data in the group and it disagrees with itself. Four weeks of a standardised extract twice a day failed to beat placebo on sleep diaries in people with primary insomnia. A slightly smaller twice-daily dose over the same four weeks did move questionnaire scores in nursing-home residents. Twelve trials pooled in 2024 land mildly in its favour.

Its anxiety evidence is stronger and uses a much larger dose. A long-term trial in generalised anxiety disorder ran 1,500 mg a day, and a meta-analysis covering anxiety and sleep quality sets the two literatures side by side. NCCIH notes the ragweed cross-reaction, which is the one allergy worth flagging in this group.

Passionflower has three human results and each used a different preparation, which is unusual and inconvenient. A single capsule taken an hour and a half before day surgery lowered anxiety scores at the point of admission. A month-long comparison with oxazepam was run on a tincture measured in drops. The study people usually mean when they say passionflower helps sleep gave a cup of tea a night for a week and never printed a weight at all. A 2024 stress and sleep trial leaves its extract amount out of the abstract as well.

That matters commercially, because a 2025 survey found passionflower food supplements and registered herbal medicines are not interchangeable on content.

Skullcap has the least of the three. A two-week crossover dosed healthy volunteers three times a day and found nothing on an anxiety inventory, in a group who were not anxious when they started. A 2025 study ran a characterised extract for eight weeks in sixty-six people with mild to moderate insomnia, with a sleep questionnaire as its primary outcome. Two studies is thin, and it is more than several shelf ingredients manage.

If a reader wants one ingredient in this category with a clean recent trial, this is currently it.

The ten-week trial that made its reputation enrolled people whose insomnia had been confirmed on a wrist monitor rather than by questionnaire, dosed a root extract morning and evening, and moved three separate sleep measures at once. An earlier two-month study used the same morning-and-evening schedule for stress and anxiety instead.

A 2026 head-to-head compared ashwagandha root extract, melatonin, both together and placebo over eight weeks, which is the most directly useful comparison anybody has published for this aisle. A 2025 meta-analysis covers its wider mental-health results.

There is a signal beside it and burying it would be dishonest. The national registry of drug-induced liver injury lists ashwagandha, and a review of the published cases sets out what was seen in each. The frequency is low and the record is real, which together make this an ingredient somebody with a liver condition should weigh rather than assume. NCCIH covers both halves of that.

Some names appear on these labels because a mechanism is plausible rather than because a result exists. That is a legitimate thing for a formulator to do and it is worth a reader being able to spot.

Taurine is the clearest case. Nobody has run a human sleep trial of it at any amount. A neurological review explains the reasoning, which rests on receptor activity rather than on an outcome anybody measured. Its systematic review of human work is about cognition, and an exposure assessment is a reminder of where most people actually meet it, which is an energy drink.

Goji is a milder version of the same problem. Its best-known study was a fortnight of a standardised juice, measured in millilitres, with sleep quality one item among many on a subjective questionnaire. Nobody can convert a daily glass of juice into a share of a capsule and stay honest about it. A pharmacology and safety review covers the fruit itself, and one published case involves an anticoagulant.

St. John’s wort is the one to be most careful with when it appears in a sleep formula. Its own evidence base is for depressive symptoms rather than for sleep, and it carries the best-documented interaction profile of any herb on a supermarket shelf: a benzodiazepine left the bloodstream about twice as fast at its usual clinical dose, and a contraceptive reached lower levels, with bleeding between periods. A 2020 review ties the strength of that effect to one constituent of the plant, and a review of clinical reports collects the wider list. NCCIH summarises it for a general reader.

A guide that did not say this would be incomplete, and it costs the desk publishing it nothing to say.

A fixed rising time is the most powerful lever anybody has over their own sleep, it is free, and it works within about two weeks. Getting up at the same hour every day, including at weekends, does more than any capsule in this category.

Light comes second. Bright light in the morning and dim light in the last hour before bed is the same mechanism melatonin is trying to borrow, applied at the source rather than in a capsule.

Caffeine has a longer tail than most people allow for, and alcohol shortens the time taken to fall asleep while fragmenting the second half of the night, which is the half that matters.

And where insomnia has run for months, cognitive behavioural therapy for insomnia outperforms everything on a supplement shelf and is not a capsule. Snoring with pauses, gasping at night or sleepiness at the wheel point somewhere else again, and that somewhere is an assessment.

The honest place for a supplement is alongside those, not instead of them. NCCIH’s guidance on using supplements wisely is a sensible page for anybody starting out.

The rule that produces this is short. A supplement sold in the United States is allowed to talk about structure and function. It is not allowed to talk about diseases, and insomnia is one.

So “supports sleep” and “supports a calm evening” are the ceiling for everybody in the aisle, and every bottle carries the same line of small print underneath.

That is why the language on these products all sounds the same, and it is why the interesting information is never in the claim. It is in the panel: which ingredients, how much of each, which plant part, and which form.

A reader who learns to skip the front of the bottle and read the back of it has learned the only durable skill in this category. The next guide is a checklist for doing exactly that.